It is not negligible - there is enough data already. The benefits depends on age (above 40) and comorbidities. Given we have a decently working antiviral and mo

It is not negligible - there is enough data already. The benefits depends on age (above 40) and comorbidities. Given we have a decently working antiviral and monoclonal antibodies, the vaccine has little appeal today. Vaccinating healthy kids will be damned in the very immediate future once this administration is gone!